Transgen Hergestellte Fusionsproteine
Anmelder: GTC Biotherapeutics, Inc., AstraZeneca UK Limited, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, Astrazeneca Limited, The United States of America, represented by The Secretary, Dept. of Health and Human Services, the Natl. Institutes of Health 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP1220864
- Aktenzeichen
- EP00963586
- Anmeldetag
- 18. September 2000
- Veröffentlichung
- 10. Juli 2002
- Rechtsraum
- EP
- IPC
- C07H21/04C07K1/00C07K14/00C12N15/00C12N15/12C12N15/13C12P21/00
Abstract
Für dieses Patent liegt uns kein Abstract vor.
Anmelder
- Firmen
- GTC Biotherapeutics, Inc.
AstraZeneca UK Limited
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Astrazeneca Limited
The United States of America, represented by The Secretary, Dept. of Health and Human Services, the Natl. Institutes of Health - Land
- 🇺🇸 USA
Britisch-schwedischer Pharmakonzern mit Sitz in Cambridge, Großbritannien, entstanden 1999 aus der Fusion von Astra AB und Zeneca Group. AstraZeneca entwickelt Arzneimittel und Impfstoffe in Onkologie, Kardiologie, Atemwegserkrankungen und Immunologie.
2.618 Patente in unserer Datenbank